Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2021

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2021

The Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2021 report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer monoclonal antibody partnering deals
Most active companies in cancer monoclonal antibody partnering
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer monoclonal antibody partnering contract documents
Top cancer monoclonal antibody deals by value

This report provides details of the latest Cancer monoclonal antibody agreements announced in the healthcare sectors.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2014, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.


The initial chapters of this report provide an orientation of Cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer monoclonal antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer monoclonal antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active Cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of Cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2014. The chapter is organized by specific Cancer monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Cancer monoclonal antibody partnering company A-Z, deal type definitions and Cancer monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Cancer monoclonal antibody partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer monoclonal antibody technologies and products.

Key benefits

Global Cancer Monoclonal Antibody Partnering Terms & Agreements provides the reader with the following key benefits:

In-depth understanding of cancer monoclonal antibody deal trends since 2014
Access to headline, upfront, milestone and royalty data
Comprehensive access to over 550 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
Identify most active companies in cancer monoclonal antibody partnering
Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spot the emerging companies in the cancer monoclonal antibody area

Report scope

Global Cancer Monoclonal Antibody Partnering Terms & Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

Cancer Monoclonal Antibody Partnering Terms & Agreements includes:

Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2014
Analysis of cancer monoclonal antibody deal structure
Access to headline, upfront, milestone and royalty data
Access to over 550 cancer monoclonal antibody deal records
The leading cancer monoclonal antibody deals by value since 2014

In Cancer Monoclonal Antibody Partnering Terms & Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target
Monoclonal antibody type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Monoclonal Antibody Partnering Terms & Agreements report provides comprehensive access to available deals and contract documents for over 550 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?


  • Executive Summary
  • Introduction
  • Trends in cancer monoclonal antibody dealmaking
    • Introduction
    • Cancer monoclonal antibody partnering over the years
    • Most active cancer monoclonal antibody dealmakers
    • Cancer monoclonal antibody partnering by deal type
    • Cancer monoclonal antibody partnering by therapy area
    • Deal terms for cancer monoclonal antibody partnering
      • Cancer monoclonal antibody partnering headline values
        • Table Cancer monoclonal antibody deals with a headline value
      • Cancer monoclonal antibody deal upfront payments
        • Table Cancer monoclonal antibody deals with an upfront value
      • Cancer monoclonal antibody deal milestone payments
        • Table Cancer monoclonal antibody deals with a milestone value
      • Cancer monoclonal antibody royalty rates
        • Table Cancer monoclonal antibody deals with a royalty rate value
  • Leading cancer monoclonal antibody deals
    • Introduction
    • Top Cancer monoclonal antibody deals by value
      • Table Top Cancer monoclonal antibody deals by value since 2014
  • Most active cancer monoclonal antibody dealmakers
    • Introduction
    • Most active cancer monoclonal antibody dealmakers
    • Most active cancer monoclonal antibody partnering company profiles
      • Merck and Co
      • Bristol-Myers Squibb
      • Pfizer
      • Merck KGaA
      • Genentech
      • AstraZeneca
      • Roche
      • Immunomedics
      • MD Anderson Cancer Center
      • Eli Lilly
      • Forty Seven
      • MedImmune
      • Innovent Biologics
      • BeiGene
      • I-mab
      • National Cancer Institute
      • PharmAbcine
      • Seattle Genetics
      • Selexis
      • Amgen
      • Arcus Biosciences
      • Daiichi Sankyo
      • Incyte
      • Junshi Biosciences
      • Macrogenics
  • Cancer monoclonal antibody contracts dealmaking directory
    • Introduction
    • Cancer monoclonal antibody contracts dealmaking directory
  • Cancer monoclonal antibody dealmaking by technology type
    • Monoclonal antibodies
      • Chimeric mAb
      • Humanized mAb
      • Human mAb
      • Murine mAb
  • Partnering resource center
    • Online partnering
    • Partnering events
    • Further reading on dealmaking
  • Appendices
    • Cancer monoclonal antibody deals by company A-Z
      • 3D Medicines
      • 3SBio
      • 4D Pharma
      • Abbvie
      • AbClon
      • Abmuno Therapeutics
      • Abpro
      • Abveris
      • Abzena
      • Accord Healthcare
      • Acerta Pharma
      • Actinium Pharmaceuticals
      • Adaptimmune
      • Adaptive Biotechnologies
      • Adlai Nortye
      • Aduro BioTech
      • Advaxis
      • Aeglea BioTherapeutics
      • AffaMed Therapeutics
      • Affimed Therapeutics
      • Affinita Biotech
      • AGC Biologics
      • Agenus Bio
      • Ajinomoto
      • Alligator Bioscience
      • Almac Group
      • Alphamab Biopharmaceuticals
      • Alvogen
      • ALX Oncology
      • Ambrx
      • Amgen
      • Amneal Pharmaceuticals
      • AnaptysBio
      • Antengene
      • Anthera Pharmaceuticals
      • Antigen Express
      • Apceth
      • Apeiron Biologics
      • Aperion Biologics
      • Apexigen
      • Aptevo Therapeutics
      • Arch Oncology
      • Arcus Biosciences
      • ArGEN-X
      • Argenx
      • Array Biopharma
      • Ascenion
      • Ascentage Pharma
      • Aslan Pharma
      • Astellas Pharma
      • Astex Pharmaceuticals
      • AstraZeneca
      • Atara Biotherapeutics
      • Athenex
      • Atlab Pharma
      • Atlante Biotech
      • ATP
      • Aulos Bioscience
      • AVEO Oncology
      • Aytu BioPharma
      • Basilea Pharmaceutica
      • Bavarian Nordic
      • Baxalta
      • Bayer
      • BeiGene
      • BerGenBio
      • Betta Pharmaceuticals
      • Biametrics
      • Binex
      • Bio-Manguinhos/Fiocruz
      • Bio-Thera Solutions
      • BioAtla
      • Bioceros
      • BiocerOX Products
      • Biodesix
      • Biogen
      • BioInvent
      • BiolineRX
      • Biolojic Design
      • BioMarker Strategies
      • Biomm
      • Biomunex Pharmaceuticals
      • Bioncotech Therapeutics
      • Biond Biologics
      • BioNTech
      • Biothera Pharmaceuticals
      • BioXcel
      • Bio Farma
      • BliNK Biomedical
      • BliNK Therapeutics
      • Boehringer Ingelheim
      • Boston Immune Technologies and Therapeutics
      • Bpifrance
      • Bristol-Myers Squibb
      • C-Bridge Capital
      • California Institute for Regenerative Medicine
      • Calithera Biosciences
      • Cancer Prevention and Research Institute of Texas
      • Cancer Research Technology
      • Cancer Research UK
      • CanCure
      • Candel Therapeutics
      • Cantargia
      • Caris Life Sciences
      • CBT Pharmaceuticals
      • CDI Laboratories
      • Celgene
      • Celldex Therapeutics
      • Celltrion
      • Cell Signaling Technology
      • Centre for Drug Research and Development (CDRD)
      • Checkmate Pharmaceuticals
      • Checkpoint Therapeutics
      • Chi-Med
      • Chiome Bioscience
      • Cilag AG
      • Cipla
      • City of Hope Comprehensive Cancer Center
      • Clal Biotech
      • Clinica Universidad Navarra
      • Clovis Oncology
      • CMAB Biopharma
      • CMC Biologics
      • Coherus Biosciences
      • Cold Genesys
      • Columbia University
      • Compugen
      • Conkwest
      • Corvus Pharmaceuticals
      • Covalab
      • Crescendo Biologics
      • Crown Bioscience
      • CStone Pharmaceuticals
      • Cue Biopharma
      • Cullinan Oncology
      • Curative Biotechnology
      • CureTech
      • Curie-Cancer
      • CytomX Therapeutics
      • Cytovance Biologics
      • Daiichi Sankyo
      • Dako
      • Debiopharm
      • Diaprost
      • Distributed Bio
      • DNAtrix
      • Dynavax Technologies
      • EFFECTOR Therapeutics
      • Eisai
      • Elevation Oncology
      • Eleven Biotherapeutics
      • Eli Lilly
      • ElsaLys Biotech
      • EMD Millipore
      • EMD Serono
      • Enumeral Biomedical
      • Enzo Biochem
      • EpiThany
      • Essex Bio-Technology
      • Eucure Biopharma
      • Eureka Therapeutics
      • Eurofarma
      • European Union Regional Development Fund
      • EUSA Pharma
      • Eutilex
      • Everest Medicines
      • Exelixis
      • FarmaMondo Group
      • Faron Pharmaceuticals
      • Fate Therapeutics
      • Five Prime Therapeutics
      • FLX Bio
      • Forty Seven
      • Fosun Kite Biotechnology
      • Fred Hutchinson Cancer Research Center
      • Fuhong Hanlin
      • Galaxy Biotech
      • Gallus Biopharmaceuticals
      • GamaMabs Pharma
      • Genentech
      • Genexine
      • Genmab
      • Genome and Company
      • Genor Biopharma
      • Genprex
      • GenScript Biotech
      • Gen Ilac
      • Georgetown University
      • Gilead Sciences
      • GlaxoSmithKline
      • Glenmark Pharmaceuticals
      • Glycotope Biotechnology
      • Glythera
      • Goodwin Biotechnology
      • Gossamer Bio
      • Gradalis
      • Gritstone Oncology
      • H-Immune
      • H3 Biomedicine
      • Halozyme Therapeutics
      • Harbour Biomed
      • Heidelberg Pharma
      • Henlius Biotech
      • Highlight Therapeutics
      • Hikma Pharmaceuticals
      • Hoffmann La Roche
      • Hospira
      • Hualan Genetic
      • Humanigen
      • Hummingbird Bioscience
      • Hutchison MediPharma
      • HUYA Bioscience
      • I-mab
      • I2 Pharmaceuticals
      • IBA Molecular Imaging
      • IcanoMAB
      • IDD Biotech
      • Idera Pharmaceuticals
      • Illumina
      • ImaginAb
      • ImCheck Therapeutics
      • ImClone Systems
      • Immatics Biotechnologies
      • ImmuneOncia Therapeutics
      • Immune Design
      • Immune Pharmaceuticals
      • Immunitas Therapeutics
      • ImmunoChina Pharmaceuticals
      • Immunocore
      • ImmunoGen
      • Immunomedics
      • Immunovaccine
      • Immutep
      • IMPACT Therapeutics
      • IMV
      • Incyte
      • Infinity Pharmaceuticals
      • Innate Pharma
      • Innovent Biologics
      • Inserm
      • Inserm Transfert
      • Institute of Biophysics
      • Intensity Therapeutics
      • Invenra
      • InxMed
      • IONTAS
      • IO Biotech
      • Ipca Laboratories
      • Ipsen
      • IRBM
      • ISA Pharmaceuticals
      • IsoTherapeutics
      • Isotopia Molecular Imaging
      • ITeos Therapeutics
      • Janssen Biotech
      • Janssen Pharmaceuticals
      • Janssen Research & Development
      • Jazz Pharmaceuticals
      • JHL Biotech
      • Jiangsu Alphamab
      • Jiangsu Hansoh Pharmaceutical
      • Jiangsu Hengrui Medicine
      • Johnson & Johnson Innovation
      • Johnson Matthey
      • Johns Hopkins University
      • Jounce Therapeutics
      • Juno Therapeutics
      • Junshi Biosciences
      • KAHR Medical
      • Kalbe Genexine Biologics
      • Kelun-Biotech Biopharmaceutical
      • Kiniksa Pharmaceuticals
      • Kintor
      • Kite Pharma
      • Kitov Pharma
      • Kolltan Pharmaceuticals
      • Kymab
      • Kyowa Hakko Kirin
      • Laekna
      • Lassen Therapeutics
      • Leads Biolabs
      • Leap Therapeutics
      • Lee's Pharmaceutical
      • Leica Biosystems
      • LEO Pharma
      • Les Laboratoires Servier
      • Leukemia & Lymphoma Society
      • LG Life Sciences
      • Linnaeus Therapeutics
      • Lonza
      • Lumos Pharma
      • Lupagen
      • Lyvgen Biopharma
      • Mabion
      • MAbsolve
      • MabVax Therapeutics
      • MAbXience
      • MAB Discovery
      • Macquarie University
      • Macrogenics
      • MAIA Biotechnology
      • Manhattan BioSolutions
      • Mapp Biopharmaceutical
      • Massachusetts General Hospital
      • Mayo Clinic
      • MD Anderson Cancer Center
      • Medical Research Council
      • MedImmune
      • Medison Pharma
      • Medivation
      • Memorial Sloan Kettering Cancer Center
      • Merck and Co
      • Merck KGaA
      • Merck Sharpe & Dohme
      • Mereo BioPharma
      • Merrimack Pharmaceuticals
      • Mersana Therapeutics
      • Merus
      • MicroConstants
      • Minomic
      • Mitra Biotech
      • Mitsubishi Tanabe Pharma
      • Moleculin Biotech
      • MorphoSys
      • Morphotek
      • Mount Sinai Health System
      • MSD
      • Mundipharma
      • Mustang Bio
      • Mylan Laboratories
      • Mylan Pharmaceuticals
      • Myriad Genetics
      • NantBioScience
      • NantCell
      • NantKwest
      • NantWorks
      • Nascent Biotech
      • National Cancer Institute
      • National Center for Tumor Diseases
      • National Comprehensive Cancer Network (NCCN)
      • National Institutes of Health
      • NCIC Clinical Trials Group
      • Nektar Therapeutics
      • Nelum Pharma
      • NeoBiotechnologies
      • NeoImmuneTech
      • Neon Therapeutics
      • NETRIS Pharma
      • NeuClone
      • Neuroblastoma and Medulloblastoma Translational Research
      • Nexvet
      • NKMax America
      • Northern Biologics
      • NovalGen
      • Novartis
      • Novelogics Biotechnology
      • NovImmune
      • Novocure
      • Novo Nordisk
      • Noxopharm
      • Noxxon Pharma
      • Numab
      • Olivia Newton-John Cancer Research Institute
      • Oncobiologics
      • OncoCare Therapeutics
      • OncoImmune
      • Oncologie
      • Oncolytics Biotech
      • OncoMed Pharmaceuticals
      • OncoQuest
      • OncoSec Medical
      • Oncosynergy
      • Oncothyreon
      • Oncternal Therapeutics
      • Oncurious
      • Ono Pharmaceutical
      • Open Monoclonal Technology
      • OSE Immunotherapeutics
      • Oxford BioTherapeutics
      • Panacea Pharmaceuticals
      • Pascal Biosciences
      • Patheon
      • PDS Biotechnology
      • Pelican Therapeutics
      • Peregrine Pharmaceuticals
      • Personalis
      • Personal Genome Diagnostics
      • Pfizer
      • Phanes Therapeutics
      • PharmAbcine
      • Pharmacyclics
      • Pharmapark
      • Pierre Fabre
      • Pionyr Immunotherapeutics
      • PlantForm
      • PlantPraxis Biotecnologia
      • Pneuma Respiratory
      • Poseida Therapeutics
      • Precision Biologics
      • Prestige BioPharma
      • ProBioGen
      • Progenics Pharmaceuticals
      • ProtoKinetix
      • PT Etana Biotechnologies
      • PULSALYS
      • QBiotics
      • Quantum Leap Health Care Collaborative
      • Queensland Institute of Medical Research (QIMR)
      • Quest PharmaTech
      • Rakuten Medical
      • RefleXion Medical
      • Regeneron Pharmaceuticals
      • Rentschler Biotechnologie
      • Replimune
      • Rexahn Pharmaceuticals
      • Roche
      • Rockefeller University
      • Roswell Park Cancer Institute
      • Royalty Pharma
      • Saccharo
      • Samsung Bioepis
      • Samsung Biologics
      • Samyang Biopharmaceuticals
      • Sanofi-Aventis
      • Sanofi
      • Sarah Cannon Research Institute
      • SATT Sud-Est
      • Scandion Oncology
      • Schrodinger
      • SciClone Pharmaceuticals
      • Scripps Research Institute
      • Seattle Genetics
      • Sea Lane Biotechnologies
      • Seismic Bio
      • Selecxine
      • Selexis
      • SELLAS Life Sciences Group
      • Sensei Biotherapeutics
      • Serum Institute of India
      • Seven and Eight Biopharmaceuticals
      • Shenogen Pharma
      • Shenzhen Chipscreen Biosciences
      • Shire Pharmaceuticals
      • Simcere Pharmaceuticals
      • Sirnaomics
      • Sorrento Therapeutics
      • Sosei Heptares
      • Specialized Medical Services-oncology
      • Spring Bank Pharmaceuticals
      • Stand Up To Cancer
      • Strata Oncology
      • Sud Investments
      • Surface Oncology
      • Swedish Orphan Biovitrum
      • Swixx Biopharma
      • Symphogen
      • Syndax Pharmaceuticals
      • Synlogic
      • Syros Pharmaceuticals
      • Taiho
      • Takeda Pharmaceutical
      • TARIS Biomedical
      • Telix Pharmaceuticals
      • Tempest Therapeutics
      • TeneoBio
      • Tesaro
      • Tessa Therapeutics
      • Tetragenetics
      • TetraLogic Pharmaceuticals
      • Teva Pharmaceutical Industries
      • TG Therapeutics
      • Theradiag
      • Theranyx
      • Thermo Fisher Scientific
      • ThromboGenics
      • Tikcro Technologies
      • TILT Biotherapeutics
      • Tiziana Life Sciences
      • Tizona Therapeutics
      • Tmunity Therapeutics
      • Torque Therapeutics
      • TPG Capital
      • TRACON Pharmaceuticals
      • Transgene
      • TransPerfect Life Sciences
      • Trianni
      • Trieza Therapeutics
      • Trio Pharmaceuticals
      • Turgut Ilaclari
      • Twist Bioscience
      • UbiVac
      • UCB
      • UMass Memorial Medical Center
      • Universite Claude Bernard Lyon
      • University of Bergen
      • University of British Columbia
      • University of California, San Diego
      • University of California Los Angeles
      • University of California San Francisco
      • University of Cologne
      • University of Illinois at Chicago
      • University of Massachusetts Medical School
      • University of Minnesota
      • University of New Mexico
      • University of Nottingham
      • University of Wisconsin Carbone Cancer Center (UWCCC)
      • Unum Therapeutics
      • UroGen Pharma
      • Vaccinex
      • Valneva
      • Vaximm
      • Vcell Healthcare
      • Vedanta Biosciences
      • Ventana Medical Systems
      • Verastem
      • Verseau Therapeutics
      • VIB
      • Viela Bio
      • Viralytics
      • Vyriad
      • Wilex
      • WindMIL Therapeutics
      • Wuxi Shuangliang Biotechnology
      • XBiotech
      • Xencor
      • Xoma
      • Y-Biologics
      • Y-mAbs Therapeutics
      • Yale University
      • Yeda Research and Development Company
      • ZAI Laboratory
      • Zenoaq
      • Zenyaku Kogyo
      • Zhejiang Bossan Pharmaceutical
      • Zhejiang Hisun Pharmaceutical
      • Zhejiang Huahai Pharmaceutical
      • Zydus Cadila
    • Cancer monoclonal antibody deals by stage of development
      • Discovery
      • Preclinical
      • Phase I
      • Phase II
      • Phase III
      • Regulatory
      • Marketed
      • Formulation
    • Cancer monoclonal antibody deals by deal type
      • Asset purchase
      • Bigpharma outlicensing
      • Co-development
      • Collaborative R&D
      • Co-market
      • Contract service
      • Co-promotion
      • CRADA
      • Development
      • Distribution
      • Equity purchase
      • Evaluation
      • Grant
      • Joint venture
      • Licensing
      • Manufacturing
      • Marketing
      • Material transfer
      • Option
      • Promotion
      • Research
      • Royalty financing
      • Settlement
      • Spin out
      • Sub-license
      • Supply
      • Technology transfer
      • Termination
    • Cancer monoclonal antibody deals by therapy area
      • Oncology
      • Adenocarcinoma
      • Bile duct cancer
      • Bladder cancer
      • Bone cancer
      • Brain cancer
      • Glioblastoma
      • Breast cancer
      • Cervical cancer
      • Colorectal cancer
      • Endometrial
      • Esophageal cancer
      • Gastric cancer
      • Head and neck cancer
      • Kidney cancer
      • Leukemia
      • Acute lymphoblastic leukemia
      • Acute myelogenous leukemia
      • Chronic lymphocytic leukemia
      • Chronic myelogenous leukemia
      • Liver cancer
      • Lung cancer
      • Non small cell lung cancer
      • Small cell lung cancer
      • Lymphoma
      • Hodgkin's lymphoma
      • Non Hodgkin's lymphoma
      • Melanoma
      • Metastases
      • Multiple myeloma
      • Neuroblastoma
      • Ovarian cancer
      • Pancreatic cancer
      • Prostate cancer
      • Renal cell carcinoma
      • Sarcoma
      • Solid tumors
      • Squamous cell carcinoma
      • Cachexia
      • Cancer pain
      • Thyroid cancer
      • Urothelial cancer
    • Deal type definitions
  • About Wildwood Ventures
    • Current Partnering
    • Current Agreements
    • Recent report titles from Current Partnering

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook